Genmab A earnings were $1.2B for the trailing 12 months ending Jun 30, 2025, with 62.5% growth year over year. The latest GMAB earnings report on Jun 30, 2025 announced Q2 2025 earnings of $336.0M, up 72.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GMAB reported annual earnings of $1.1B, with 80.2% growth.
GMAB past earnings growth
How has GMAB's earnings growth performed historically?
On GMAB's earnings call on Invalid Date, Genmab A (NASDAQ: GMAB) reported Q2 2025 earnings per share (EPS) of $0.54, up 72.7% year over year. Total GMAB earnings for the quarter were $336.00 million. In the same quarter last year, Genmab A's earnings per share (EPS) was $0.32.
As of the last Genmab A earnings report, Genmab A is currently profitable. Genmab A's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $1.25 billion, a 58.19% increase year over year.
What was GMAB's earnings growth in the past year?
As of Genmab A's earnings date in Invalid Date, Genmab A's earnings has grown 62.49% year over year. This is 30.93 percentage points higher than the US Biotechnology industry earnings growth rate of 31.56%. GMAB earnings in the past year totalled $1.25 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.